Price movement over the last 24 hours
ADMA Biologics Inc vs KraneShares CSI China Internet ETF — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while KraneShares CSI China Internet ETF trades at $26.46. Which is the better fit depends on your goals.
| ADMA | KWEB | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $20.38 | $42.94 |
52-Week Low | $7.60 | $23.63 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
KWEB, the KraneShares CSI China Internet ETF, trades at $25.59, up 2.44% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF offers concentrated exposure to Chinese internet and AI companies, currently near 52-week lows, benefiting from AI-driven growth and government support. Recent news highlights China's factory rebound and substantial AI infrastructure investments.
The outlook for KWEB is mixed; attractive valuations and AI tailwinds present opportunities, but risks include US-China tensions and China's economic volatility. Analyst sentiment is cautious due to geopolitical and regulatory uncertainties, though long-term growth potential in Chinese tech remains.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →